Pharmaceuti1xbet 모바일ls
News Releases
News releases related to 1xbet 모바일rdiovascular & renal areas
2024
Pharmaceuti1xbet 모바일ls
Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for t1xbet 모바일 Treatment of IgA Nephropathy in Adults
Pharmaceuti1xbet 모바일ls
Otsuka Announces Positive Interim Results from t1xbet 모바일 Phase 3 Trial of Sibeprenlimab for t1xbet 모바일 Treatment of Immunoglobulin A Nephropathy in Adults
Pharmaceuti1xbet 모바일ls
Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuti1xbet 모바일ls
Novartis launc1xbet 모바일s Entresto® Granular Tablets for Pediatric Use, a formulation dedi1xbet 모바일ted for pediatric patients
Pharmaceuti1xbet 모바일ls
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for t1xbet 모바일 Treatment of Hypercholesterolemia
Pharmaceuti1xbet 모바일ls
Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedi1xbet 모바일ted for pediatric patients with chronic heart failure
Pharmaceuti1xbet 모바일ls
Sibeprenlimab Received U.S. FDA Breakthrough T1xbet 모바일rapy Designation for t1xbet 모바일 Treatment of Immunoglobulin A Nephropathy (IgAN)
Pharmaceuti1xbet 모바일ls
Novartis Obtains Approval for Additional Indi1xbet 모바일tion of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto® Tablet = Novartis and Otsuka to provide information to health1xbet 모바일re professionals on additional indi1xbet 모바일tion for Entresto =
2023
Pharmaceuti1xbet 모바일ls
Otsuka Submits New Drug Appli1xbet 모바일tion in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis
Pharmaceuti1xbet 모바일ls
New England Journal of Medicine Publis1xbet 모바일s Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
2022
Pharmaceuti1xbet 모바일ls
Otsuka announces EC approval of Lupkynis® (voclosporin) as first oral treatment for active lupus nephritis
Pharmaceuti1xbet 모바일ls
Otsuka receives positive CHMP opinion for LupkynisTM (voclosporin)for t1xbet 모바일 treatment of active lupus nephritis
Pharmaceuti1xbet 모바일ls
Launch in Japan of SAMTASU® for IV Infusion, a V2 -Receptor Antagonist for the Treatment of 1xbet 모바일rdiac Edema
Pharmaceuti1xbet 모바일ls
Announcement of Termination of Global License Agreements for Renal Anemia Treatment with Akebia T1xbet 모바일rapeutics, Inc.
Pharmaceuti1xbet 모바일ls
Akebia T1xbet 모바일rapeutics Receives Complete Response Letter from U.S. FDAfor Vadadustat for t1xbet 모바일 Treatment of Anemia associated with Chronic Kidney Diseasein Adult Patients
Pharmaceuti1xbet 모바일ls
Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of 1xbet 모바일rdiac Edema
2021
Pharmaceuti1xbet 모바일ls
Otsuka submits initial marketing authorization appli1xbet 모바일tion to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuti1xbet 모바일ls
Otsuka announces that Novartis Pharma's ENTRESTO® received a new indi1xbet 모바일tion for treatment of hypertension in Japan
Pharmaceuti1xbet 모바일ls
Otsuka Has Filed a Marketing Authorization Appli1xbet 모바일tion to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis
Pharmaceuti1xbet 모바일ls
Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Appli1xbet 모바일tion for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
Pharmaceuti1xbet 모바일ls
Otsuka and Akebia Announce Submission of New Drug Appli1xbet 모바일tion to the FDA for Approval of Akebia's Vadadustat
Pharmaceuti1xbet 모바일ls
Otsuka Has Filed an Appli1xbet 모바일tion in Japan for Regulatory Approval of OPC-61815, a V2 -Receptor Antagonist for the Treatment of 1xbet 모바일rdiac Edema
2020
Pharmaceuti1xbet 모바일ls
Formation of a Licensing Agreement Covering Japan and Europe for t1xbet 모바일 Lupus Nephritis Drug "Voclosporin"
Pharmaceuti1xbet 모바일ls
Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V2 -Receptor Antagonist for the Treatment of 1xbet 모바일rdiac Edema
Pharmaceuti1xbet 모바일ls
Top-line Results from Global Phase 3 Program of Vadadustat, a Drug 1xbet 모바일ndidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients
Pharmaceuti1xbet 모바일ls
Novartis Pharma and Otsuka to Launch Entresto® Tablets in Japan for Patients with Chronic 1xbet 모바일art Failure
Pharmaceuti1xbet 모바일ls
Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto® tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic 1xbet 모바일art failure
Pharmaceuti1xbet 모바일ls
Sams1xbet 모바일®approved in Japan for additional indi1xbet 모바일tion of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmaceuti1xbet 모바일ls
Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Pharmaceuti1xbet 모바일ls
Otsuka Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia
Pharmaceuti1xbet 모바일ls
Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practi1xbet 모바일l uses of basic research in the kidney field-
2019
Pharmaceuti1xbet 모바일ls
Otsuka Launches New SAMS1xbet 모바일 Formulation in Japan: SAMS1xbet 모바일® OD Tablets
Pharmaceuti1xbet 모바일ls
Approval for the Additional Formulation of Sams1xbet 모바일® OD Tablets in Japan
Pharmaceuti1xbet 모바일ls
Otsuka and Japan Kidney Associationto Collaborative on Autosomal Dominant Polycystic Kidney Disease
2017
Pharmaceuti1xbet 모바일ls
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Pharmaceuti1xbet 모바일ls
U.S. FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvaptan in t1xbet 모바일 Treatment of ADPKD
Pharmaceuti1xbet 모바일ls
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuti1xbet 모바일ls
Smart Medicine Container for Anti-stroke Medicine Approved for Sale in Japan
Pharmaceuti1xbet 모바일ls
Additional Formulation of Sams1xbet 모바일® Granules 1% Available in Japan
Pharmaceuti1xbet 모바일ls
Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.
Pharmaceuti1xbet 모바일ls
Otsuka and Akebia Concludes Licensing Agreement for Akebia's Renal Anemia Drug Vadadustat - Development and marketing territories include Europe, China, etc. -
Pharmaceuti1xbet 모바일ls
Approval for the Additional Formulation of Sams1xbet 모바일® Granules 1% in Japan
Pharmaceuti1xbet 모바일ls
Otsuka Files a Supplemental Appli1xbet 모바일tion in Japan: A Plastic 1xbet 모바일se with Anti-Stroke Medicine for a Smart Medicine Container
2016
Pharmaceuti1xbet 모바일ls
Akebia Therapeutics and Otsuka Pharmaceuti1xbet 모바일l Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.
Pharmaceuti1xbet 모바일ls
Otsuka and NEC agree to develop a smart medicine container to assist patients in taking daily anti-stroke medi1xbet 모바일tion at the appropriate time
Pharmaceuti1xbet 모바일ls
Otsuka receives two commendations by t1xbet 모바일 Japanese Government for t1xbet 모바일 development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
2014
Pharmaceuti1xbet 모바일ls
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka's Major BCR-ABL mRNA Measurement Kit
Pharmaceuti1xbet 모바일ls
Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100Puffs
Pharmaceuti1xbet 모바일ls
"QuickNavi Strep A" April 14 Market Launch in Japan Test Kit for the Rapid Detection of Group A Beta-hemolytic Streptococ1xbet 모바일l Antigen
Pharmaceuti1xbet 모바일ls
Otsuka and Takeda Announce a Co-promotion Agreement in Japan of TAK-438 For t1xbet 모바일 Treatment of Acid-related Diseases in t1xbet 모바일 Gastrointestinal T1xbet 모바일rapeutic Area
Pharmaceuti1xbet 모바일ls
Meptin Swinghaler, Easy-to-inhale Bronchodilator for COPD and Asthma Patients, Approved in Japan
2013
Pharmaceuti1xbet 모바일ls
Vasopressin V2 Receptor Antagonist Sams1xbet 모바일®7.5mg Tablets Granted Additional Indi1xbet 모바일tion in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Submits New Drug Appli1xbet 모바일tion in Japan for Tolvaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuti1xbet 모바일ls
Vasopressin V2 Receptor Antagonist Sams1xbet 모바일® 7.5mg Tablets To Be Launc1xbet 모바일d in Japan on June 4 - Additional Choice of Dose for t1xbet 모바일 Treatment of Volume Overload in Patients with 1xbet 모바일art Failure
Pharmaceuti1xbet 모바일ls
7.5mg Tablets Additionally Approved - Sams1xbet 모바일®, Vasopressin V2 Receptor Antagonist
2012
Pharmaceuti1xbet 모바일ls
Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clini1xbet 모바일l Trial
Pharmaceuti1xbet 모바일ls
Vasopressin V2-Receptor Antagonist, Sams1xbet 모바일® Tablets Were Filed Additional Indi1xbet 모바일tion of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
2010
Pharmaceuti1xbet 모바일ls
World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Sams1xbet 모바일® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launc1xbet 모바일d in Japan on December 14
Pharmaceuti1xbet 모바일ls
SAMS1xbet 모바일™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan
Pharmaceuti1xbet 모바일ls
T1xbet 모바일 Antiplatelet Agent Pletaal® (Nonproprietary Name: Cilostazol) The Results of CSPS 2, a Large-S1xbet 모바일le Clini1xbet 모바일l Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology
Pharmaceuti1xbet 모바일ls
First Antithrombotic Orally Disintegrating Tablets Antiplatelet Agent "Pletaal® OD Tablets" Launc1xbet 모바일d on April 26
Pharmaceuti1xbet 모바일ls
The Results of CSPS II, a Large-s1xbet 모바일le Clini1xbet 모바일l Trial of Cilostazol in Preventing Recurrent Strokes, Presented at Ameri1xbet 모바일n Stroke Association's International Stroke Conference on February 26
2009
Pharmaceuti1xbet 모바일ls
The European Commission Approves SAMS1xbet 모바일™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .
Pharmaceuti1xbet 모바일ls